Keyron nomme un nouveau président-directeur général

Carl D Francis prend les rênes du groupe de technologies médicales axé sur le renversement du diabète, de la stéatohépatite non-alcoolique (SHNA) et de l’obésité

LONDRES, 07 févr. 2023 (GLOBE NEWSWIRE) — Keyron, le groupe de technologies médicales axé sur le renversement du diabète de type 2, de la stéatohépatite non-alcoolique (SHNA) et de l’obésité via une plateforme de dispositifs médicaux innovants, a annoncé aujourd’hui la nomination de Carl D Francis au poste de président-directeur général.

« La hausse constante de l’obésité, du diabète et de toutes les formes de stéatose hépatique constitue l’un des plus grands défis auxquels le monde est confronté aujourd’hui. Des milliards de personnes sont littéralement affectées et les chiffres ne cessent d’augmenter rapidement », a déclaré M. Francis. « La technologie de Keyron change entièrement la donne. Un traitement innovant, non-chirurgical, administré de manière endoscopique et entièrement réversible est extrêmement prometteur en tant qu’alternative aux interventions bariatriques drastiques. Je suis très fier et honoré de faire partie de Keyron. »

D’après l’American Diabetes Association, 37 millions d’Américains souffrent aujourd’hui de diabète, et 96 millions sont atteints de prédiabète. Le lien entre l’obésité et le diabète est bien établi, et selon les prévisions de la World Obesity Federation dans son Atlas 2022 récemment publié, 67 % des femmes et 51 % des hommes dans les Amériques vivront avec l’obésité (IMC ≥ 30) d’ici 2030.

La technologie brevetée de Keyron est conçue pour être une procédure ambulatoire entièrement endoscopique fournissant des avantages gastriques identiques ou supérieurs aux interventions chirurgicales de pontage gastrique, notamment un renversement du diabète de type 2 et de l’obésité, ainsi que de la SHNA et de la fibrose hépatique.

Suite à des études fructueuses réalisées sur des rongeurs en 2019 puis sur des porcs en 2022, les premiers essais de Keyron sur des humains devraient débuter au début de l’année 2024. Keyron espère obtenir l’approbation de la FDA d’ici 2028, et un lancement est prévu aux États-Unis en tant que premier marché cible. La société projette désormais de lever un tour de financement de série A de 15 millions de dollars.

Le Dr Giorgio Castagneto Gissey, président du conseil d’administration de Keyron, a commenté : « Nous sommes ravis que Carl prenne la direction de Keyron alors que nous entrons dans cette phase cruciale de notre développement. Carl apporte son énergie, sa concentration et son expérience de leadership pour s’assurer que nous réalisons notre plein potentiel. Keyron a toujours eu des membres du conseil d’administration et des conseillers médicaux de haut niveau et de renommée mondiale, et nous continuons à recruter des personnes remarquables. Nous sommes extrêmement ravis d’avoir été en mesure d’attirer Carl. »

M. Francis a précédemment occupé le poste de PDG du célèbre groupe de nanotechnologies P2i. Au cours de son mandat, le groupe est passé d’une poignée d’employés à un leadership mondial dans le domaine du nano-revêtement fonctionnel. Plus récemment, il était le PDG du groupe de technologies médicales basé au Royaume-Uni Eyoto, qui se spécialise dans les technologies avancées dans les secteurs optiques et ophtalmiques. Il a débuté sa carrière en tant qu’expert-comptable certifié aux États-Unis, est membre de Mensa et titulaire d’un BSc de l’université de Cincinnati.

CONTACT

Pour tout complément d’information, veuillez contacter :

  • Aux États-Unis – Carl D Francis à l’adresse c.francis@keyron.com ou en composant le +1 (912) 429-3800
  • En Europe – Dr Giorgio Castagneto Gissey à l’adresse gcgissey@keyron.com ou en composant le +44 7975 911101

À PROPOS DE KEYRON

Basée au Royaume-Uni, Keyron est une société qui se spécialise dans les plateformes technologiques et les dispositifs médicaux au stade préclinique visant un traitement hautement efficace pour les maladies métaboliques. La solution brevetée ForePass™ de Keyron est un dispositif médical innovant conçu pour inverser de manière sûre le diabète de type 2, ainsi que la stéatohépatite non-alcoolique (SHNA) et l’obésité. La société a déjà démontré un renversement complet de la résistance à l’insuline dans des études réalisées sur des animaux, dont elle a récemment publié les résultats dans la revue The Lancet EBioMedicine. Keyron prévoit d’effectuer prochainement des essais cliniques en Amérique du Sud et vise à mener par la suite d’autres études cliniques aux États-Unis. Ses fondateurs, directeurs, conseillers et investisseurs incluent certains des professeurs et leaders d’opinion les plus réputés et cités à l’échelle mondiale dans le domaine des maladies métaboliques. La société est soutenue par plusieurs investisseurs institutionnels basés aux États-Unis et dans la région EMOA.

GlobeNewswire Distribution ID 8744743

COVID Treatment Shows Encouraging Results in Trial, Study Says

A single-injection antiviral treatment for newly infected COVID-19 patients reduced the risk of hospitalization by half in a large-scale clinical trial, a study published Wednesday said.

Stanford University professor Jeffrey Glenn, co-author of the study published in the New England Journal of Medicine, said the new drug "showed profound benefits for vaccinated and unvaccinated people alike."

While the number of Americans dying daily of the disease caused by a coronavirus has fallen to about 500, treatments for COVID-19 remain limited. One of the most common — Paxlovid, made by Pfizer — involves taking 30 pills over five days.

The new treatment involves a single dose of pegylated interferon lambda, a synthetic version of a naturally occurring protein that infected cells secrete to defend against viral infection.

"What it does is it binds receptors on the surfaces of cells that activate our own antiviral defense mechanisms," said Glenn, a professor of medicine, microbiology and immunology who heads the Stanford Biosecurity and Pandemic Preparedness Initiative.

"So if a virus has infected the cell, it will turn on processes that aim to destroy the virus's replication," he said. "It will also send signals to neighboring cells to warn them viruses are on their way and get ready to defend yourself."

Receptors for interferon lambda are primarily in the linings of the lungs, airways and intestine — the main places COVID-19 strikes.

"We're turning on these antiviral mechanisms in the cells, the lung, where the infection is happening," Glenn said.

The phase three trial of the drug, conducted from June 2021 to February 2022, involved nearly 2,000 patients with COVID symptoms in Brazil and Canada, about 85 percent of whom had been vaccinated.

A total of 931 newly infected COVID patients were given a single injection of interferon lambda, while 1,018 participants were given a placebo.

The risk of COVID-19–related hospitalization or death from any cause was 47 percent lower in the interferon group than in the placebo group, according to the researchers.

Twenty-five of the 931 people who received the injection within seven days of exhibiting COVID symptoms were hospitalized, compared with 57 of the 1,018 who received the placebo.

Vaccinated patients treated with interferon lambda experienced a 51 percent reduction in hospitalization relative to the placebo group.

There was an 89 percent reduction in hospitalization among unvaccinated patients treated within the first three days of the onset of COVID symptoms compared with the placebo group.

Developed for hepatitis D

Glenn said interferon lambda proved effective against all COVID variants tested, including omicron, and side effects in the group receiving the injections were no greater than among the placebo recipients.

Glenn is the founder of a small biotechnology company called Eiger Biopharmaceuticals that acquired interferon lambda to develop drugs for the hepatitis delta virus.

"When COVID came, I said this would be the perfect drug for COVID," said Glenn, who left the Palo Alto company but remains on the board of directors and is an equity holder.

Eiger sought an emergency use authorization for interferon lambda from the U.S. Food and Drug Administration for COVID treatment last year, but it was not granted.

That was "very frustrating," Glenn said, though he was hopeful that publication of the study in the New England Journal of Medicine "will help encourage regulators here and around the world to find a way to get lambda into patients as soon as possible."

Source: Voice of America

World Vision East Africa Hunger Emergency Response Situation report #20 | December 2022

World Vision is responding to the impact of hunger in seven countries across East Africa and requires US $ 181 million to reach 5 million people, including 2.7 million children by April 2023. Since April 2021, we have reached more than 8.9 million people including 4.7 million children.

A deadly mix of conflict, COVID-19 and climate change have pushed more than 7.3 million people across seven countries in East Africa to the very brink of a hunger crisis. Of critical concern are vulnerable children who are experiencing high levels of malnutrition.

Conflict is one of the leading drivers of hunger globally. Every country where World Vision has a presence in East Africa is either in conflict or neighbouring a country in conflict. The region has also endured substantial climate shocks, undermining people’s ability to feed themselves. The economic consequences of the COVID-19 pandemic and the ripple effect from the war in Ukraine has driven hunger to unprecedented levels.

Impact on children and humanitarian needs, including safeguarding risks, are enormous. This challenging period could also erode human and economic development gains that have been made towards the 2030 Sustainable Development Goals across the region.

World Vision is deeply concerned for millions of children in East Africa, who are enduring a devastating hunger crisis. According to UN OCHA, about 4.9 million children are malnourished in drought-affected areas in Ethiopia, Kenya and Somalia. This is inclusive of about 1.4 million children who are severely acutely malnourished in the HOA states.

World Vision has reached more than 8.9 million people, including 4.7 million children, since April 2021. World Vision has responded with food distributions in multiple countries. Further, World Vision re-declared its multi-country response comprising Ethiopia, Kenya, Somalia, South Sudan, Sudan, Tanzania and Uganda. We aim to reach 5 million people, including 2.7 million children, by April 2023 through the second phase of the response. World Vision has been implementing a multi-country hunger emergency response in the above-mentioned countries for the last 17 months and has been able to re-purpose and raise new funds, to the tune of US $ 139 million. However, the needs have insurmountably increased and we require an additional US$ 45 million.

Source: World Vision

Zelenskyy Appearance Uncertain at EU Summit

European Union leaders are to meet Thursday for a summit dominated by migration, the economy and, not surprisingly, Ukraine. Reports suggest Ukraine President Volodymyr Zelenskyy — who arrived in London on Wednesday — may attend the Brussels summit in person.

The EU’s two-day summit comes ahead of the one-year anniversary of Russia’s invasion of Ukraine — and days after top EU officials held a summit with Zelenskyy in Kyiv.

Besides Western Europe, Ukraine’s leader has made only one other known trip outside his homeland since Russia's invasion of Ukraine; that trip was to Washington in December, where he met with United States President Joe Biden and addressed the U.S. Congress.

Zelenskyy wants several things from the Europeans, including to speed up Ukraine’s bid to join the EU, more weapons ahead of an expected Russian offensive, and more sanctions against Moscow.

Brussels is unlikely to fast-track Kyiv’s membership application. But in Kyiv last week, European Commission chief Ursula von der Leyen praised Zelenskyy’s commitment to join the bloc.

"I must say I am deeply impressed, and I want to commend you for the preciseness, the quality and the speed at which you deliver," she said. "This is phenomenal.”

Europeans already have committed billions of dollars in defense and humanitarian aid to Ukraine. Brussels is also expected to unveil a 10th sanctions package against Moscow later this month.

zeleMigration is also set to dominate the summit amid a sharp uptick in economic migrants and asylum seekers arriving in Europe this past year. That’s on top of the millions of Ukrainian war refugees.

Today, some EU member states are calling for tougher policies — and fences — against what they call “irregular” migration. Using EU funds for border fences is especially divisive.

“I think migration and asylum policy remains a very tricky issue within the EU — with the EU witnessing its biggest migration and asylum crisis since World War II,” said Pauline Veron, a policy advisor at the European Centre for Development Policy Management, a Netherlands-based think-tank.

Veron said that, even as many Europeans continue welcoming Ukrainian refugees, they are feeling rising angst about migration from Africa and elsewhere.

Source: Voice of America

Could a Sprinkle of Moon Dust Keep Earth Cool?

Whether out-of-the-box thinking or a sign of desperation, scientists on Wednesday proposed the regular transport of moon dust to a point between Earth and Sun to temper the ravages of global warming.

Ideas for filtering solar radiation to keep Earth from overheating have been kicking around for decades, ranging from giant space-based screens to churning out reflective white clouds.

But the persistent failure to draw down planet-warming greenhouse gas emissions has pushed once-fanciful geoengineering schemes toward center stage in climate policy, investment and research.

Blocking 1%-2% of the Sun's rays is all it would take to lower Earth's surface by a degree or two Celsius, roughly the amount it has warmed over the last century.

The solar radiation technique with the most traction so far is the 24/7 injection of billions of shiny sulfur particles into the upper atmosphere.

So-called stratospheric aerosol injection would be cheap, and scientists know it works because major volcanic eruptions basically do the same thing. When Mount Pinatubo in the Philippines blew its top in 1991, it lowered temperatures in the northern hemisphere by about 0.5 Celsius for nearly a year.

But there are serious potential side-effects, including the disruption of rain patterns upon which millions depend for growing food.

However, a new study in the peer-reviewed journal PLOS Climate explores the possibility of using moon dust as a solar shield.

A team of astronomers applied methods used to track planet formation around distant stars — a messy process that kicks up vast quantities of space dust — to Earth's moon.

Computer simulations showed that putting lunar dust at a gravitational sweet spot between Earth and Sun "blocked out a lot of sunlight with a little amount of mass," said lead author Ben Bromley, a professor of physics at the University of Utah.

'Balancing marbles'

The scientists tested several scenarios involving different particle properties and quantities in different orbits, looking for the one that would throw the most shade.

Moon dust worked best. The quantities needed, they said, would require the equivalent of a major mining operation on Earth.

The authors stressed that their study was designed to calculate potential impact, not logistical feasibility.

"We aren't experts in climate change or rocket science," said co-author Benjamin Bromley, a professor at the Harvard-Smithsonian Center for Astrophysics.

"We were just exploring different kinds of dust on a variety of orbits to see how effective this approach might be," he added. "We don't want to miss a game changer for such a critical problem."

Experts not involved in the study praised its methodology but doubted whether it would actually work.

"Placing moon dust at the gravity midpoint between Earth and Sun, can indeed reflect heat," said University of Edinburgh professor Stuart Haszeldine.

"But this is like trying to balance marbles on a football — within a week most dust has spun out of stable orbit."

For Joanna Haigh, an emeritus professor of atmospherics at Imperial College London, the study is a distraction.

The main problem, she said, "is the suggestion that the implementation of such schemes will solve the climate crisis whereas it just gives polluters an excuse not to act."

Source: Voice of America